In general, the primary target of fluoroquinolones in Gram-negative species such as E. coli is DNA gyrase, whereas for Gram-positive organisms such as Staphylococcus spp., the primary target is topisomerase IV 1,2.
In contrast to other veterinary fluoroquinolones, Veraflox® has an almost equivalent inhibitory potency for both targets in all bacterial species evaluated to date. Therefore, not only more bactericidal effects than ‘single target’ quinolones are induced, but also the probability for selection of resistant variants is reduced 3.
Veraflox has been found to be highly active even in the absence of protein synthesis and bacterial growth 3.
This ability to kill replicating as well as non-replicating bacteria may provide a benefit in clinical conditions where dormant bacteria persist. Additionally, this is an advantage over other classes of antibacterials, which are not bactericidal when bacteria are in the stationary phase of growth or growing slowly 4.